Endo International (NASDAQ:ENDP) (TSE:ENL) received a $7.00 price target from Canaccord Genuity in a research report issued to clients and investors on Tuesday. The firm presently has a “hold” rating on the stock. Canaccord Genuity’s price target would indicate a potential upside of 11.11% from the company’s previous close.
Several other research analysts also recently commented on ENDP. Cantor Fitzgerald set a $7.00 price target on shares of Endo International and gave the company a “hold” rating in a report on Tuesday. Barclays cut their price target on shares of Endo International from $15.00 to $10.00 and set an “equal weight” rating for the company in a report on Friday, February 23rd. ValuEngine downgraded shares of Endo International from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. JMP Securities downgraded shares of Endo International from an “outperform” rating to a “market perform” rating in a report on Monday. Finally, B. Riley initiated coverage on shares of Endo International in a report on Wednesday, February 14th. They set a “buy” rating and a $10.00 price objective for the company. Three equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Endo International presently has a consensus rating of “Hold” and an average target price of $10.32.
Endo International (NASDAQ ENDP) opened at $6.30 on Tuesday. The company has a quick ratio of 0.86, a current ratio of 1.02 and a debt-to-equity ratio of 17.00. Endo International has a fifty-two week low of $5.77 and a fifty-two week high of $14.15. The company has a market cap of $1,520.95, a price-to-earnings ratio of 1.77, a price-to-earnings-growth ratio of 2.71 and a beta of 0.29.
A number of institutional investors have recently bought and sold shares of the business. Elkfork Partners LLC bought a new stake in Endo International in the fourth quarter worth $194,000. Xact Kapitalforvaltning AB bought a new stake in Endo International in the fourth quarter worth $157,000. Hunter Associates Investment Management LLC lifted its stake in Endo International by 53.7% in the fourth quarter. Hunter Associates Investment Management LLC now owns 67,150 shares of the company’s stock worth $520,000 after purchasing an additional 23,450 shares during the last quarter. Paloma Partners Management Co bought a new stake in Endo International in the fourth quarter worth $122,000. Finally, Quantitative Investment Management LLC bought a new stake in Endo International in the fourth quarter worth $1,569,000. 92.54% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Endo International (ENDP) PT Set at $7.00 by Canaccord Genuity” was reported by Ticker Report and is owned by of Ticker Report. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3229937/endo-international-endp-pt-set-at-7-00-by-canaccord-genuity.html.
Endo International Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.